The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...

When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

Cells contain a blueprint in the form of DNA that dictates what they can make. This blueprint is converted into a message ...

Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

A newly discovered nuclear role for HSL reveals how imbalances in its location within fat cells may contribute to both ...